Polypharmacy in treatment with psychotropic drugs: The underestimated phenomenon

Current Opinion in Psychiatry

Volumn 16, Issue 6, 2003, Pages 713-718

  Karow, Anne ^a   Lambert, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antidepressant; Depression; Neuroleptics; Polypharmacy; Psychotropic drugs; Review; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; DEPRESSION; DRUG MEGADOSE; HUMAN; MENTAL DISEASE; MONOTHERAPY; PHENOMENOLOGY; POLYPHARMACY; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT;

EID: 0242643762     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200311000-00019     Document Type: Review

References (44)

1. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull 2002; 28:203-222.
2. Stahl SM. Antipsychotic polypharmacy. Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60:425-426.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564.
4. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry 2003; 64 (Suppl 2):14-18. Current knowledge of combination therapies with antidepressants. Excellent structure and useful separation of combination and augmentation therapies.
5. Salzman C. Psychotropic drug use and polypharmacy in a general hospital. Gen Hosp Psychiatry 1981; 3:1-9.
6. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61:9-15.
7. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14:33-40.
8. Zhonggyun Z, Wang PF, Gutierrez B, Gaylord BL. Polypharmacy of inpatients with schizophrenia. Am J Psychiatry Suppl 2003; pp. 62-63. Latest study investigating prescription patterns in a large sample of patients with schizophrenia in the US, showing high percentages of polypharmacy.
9. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54:55-59. Investigates antipsychotic prescribings practice and analyses different reasons for polypharmacy using a prescibers' survey in a subsample. The authors described symptom severity and being 'stuck' in switching processes as most important for combination therapy.
10. Kotzan JA, Maclean R, Wade W, et al. Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clin Ther 2002; 24:237-248. Interesting retrospective analysis of prescriptions and medical claims data. Results revealed that the prescription of concomitant SSRI therapy was strongly associated with changes in strength of dosage and products and with use of multiple prescribers and pharmacies.
11. Nunley M. Why psychiatrists in India prescribe so many drugs. Cult Med Psychiatry 1996; 20:165-197.
12. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60 (Suppl 10):31-41.
13. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002; 63:93-94. Important statements and discussion with useful and clinical relevant recommendations, which were the basis for the main conclusions of the present review.
14. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999; 60 (Suppl 10):20-30.
15. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002; 28:31-42.
16. Williams CL, Johnstone BM, Kesterson JG, et al. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999; 37 (4 Suppl Lilly):AS81-AS86.
17. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003; 12:41-48. Large study investigating prescribing practice in psychiatric inpatients. A high rate of patients received antipsychotic combination therapy.
18. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001; 39:923-933.
19. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28:17-29. Large study investigating prescribing practice in an outpatient sample with schizophrenia. There was a high rate of decanoate prescriptions.
20. Wolkowitz OM. Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 1993; 5:79-90.
21. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983; 44:326-331.
22. Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003; pp. 105-117. Interesting and critical review of new treatment options for schizophrenia.
23. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106:323-330. Excellent review of current studies and case reports investigating antipsychotic combination therapies.
24. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544-549.
25. Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol 1999; 55:533-536.
26. Koponen H, Saari K, Savolainen M, Isohanni M. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. Eur Arch Psychiatry Clin Neurosci 2002; 252:294-298.
27. Snaith RP. Antipsychotic polypharmacy and early death. Br J Psychiatry 1999; 174:368-369.
28. Senechal A, Landry P, Deschamps R, Lessard M. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002; 28 (6 Pt 1):567-569.
29. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001; 62:605-608.
30. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol 1997; 17:130-131.
31. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153:735-736.
32. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992; May (17):54-59.
33. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173:325-329.
34. Zarate CA Jr, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 2003; 5:217-225. Comprehensive review of studies of polypharmacy in bipolar disorders. Only a few controlled studies were found to investigate combination therapies in bipolar disorder. The authors recommended trials investigating combination treatments in all phases of bipolar illness to determine the most efficacious and safest combinations.
35. Fawcett JA. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. J Clin Psychiatry 2003; 64 (Suppl 5):32-37. Important summary of the available evidence and clinical considerations regarding the use of lithium augmentation in acute and maintenance treatment of unipolar and bipolar depression.
36. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl 18):4-11.
37. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002; 63:685-693. Comprehensive review of studies of combination therapy of different antidepressants in refractory depression. Discussion of the limited evidence supporting the efficacy of combination antidepressant treatment.
38. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22:379-387.
39. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002; 161:143-151. Large, controlled comparison of sertraline dose increase with sertraline combined with mianserin in major depression. After partial response to 6 weeks of sertraline, the authors suggested continued treatment with sertraline rather than any changes in medication.
40. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001; 103:66-72.
41. Wheeler Vega JA, Mortimer AM, Tyson PJ. Conventional antipsychotic prescription in unipolar depression. I: An audit and recommendations for practice. J Clin Psychiatry 2003; 64:568-574. Important study investigating antipsychotic coprescription in depression. A substantial number of antipsychotics were given without indication. The authors recommended treatment reassessments.
42. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19:299-320.
43. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry. 2001 May; 46(4):334-339.
44. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry. 1994 Feb; 55(2):44-49.